FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Vet Sci / Isolation and Characterization of Equine Lymph Node Endothel...
Veterinary sciences2025; 12(9); 905; doi: 10.3390/vetsci12090905

Isolation and Characterization of Equine Lymph Node Endothelial Cells.

Abstract: In vitro models have revolutionized our understanding of biological pathways and mechanisms, offering a viable alternative to direct patient testing. However, there is a significant lack of models for different animals, particularly equine models. This study presents a novel primary cell culture extracted from a 3-year-old horse diagnosed with multisystemic eosinophilic epitheliotropic disease. Tissue samples were collected from lymph nodes at various locations. Growth curves of extracted primary cells were analyzed and the optimal conditions were assessed. Biomarkers, such as CD31, ZO-1, CD79, Beta-catenin, E-cadherin, and LYE-1, were detected using an immunofluorescence assay, indicating that these primary cells are of endothelial origin. Initial whole-genome sequencing was performed to confirm the species' origin and to identify the number of common variations in comparison with the NIH EquCab3.0 reference genome. For the first time, the establishment of primary equine cells from lymph nodes is reported, and these can be used as an in vitro model for testing drug responses, molecular pathways, and environmental effects.
Get Full Text
Publication Date: 2025-09-18 PubMed ID: 41012830PubMed Central: PMC12474414DOI: 10.3390/vetsci12090905Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

Overview

  • This study successfully isolated and characterized primary endothelial cells from equine lymph nodes, providing a new in vitro cellular model from horses.
  • These cells were thoroughly analyzed using growth curves, biomarker detection, and genomic sequencing to confirm their identity and species origin.

Background and Purpose

  • In vitro models are essential tools for studying biological pathways, disease mechanisms, and drug responses without the need for direct testing on living organisms.
  • The lack of species-specific models, particularly for horses, limits veterinary research and testing capabilities in equine medicine.
  • The purpose of this study was to establish a primary cell culture from equine lymph nodes, enabling an in vitro platform for further investigation.

Source of Cells

  • Primary cells were isolated from lymph node tissues of a 3-year-old horse diagnosed with multisystemic eosinophilic epitheliotropic disease, providing clinically relevant biological material.
  • Tissue samples were collected from lymph nodes located at various anatomical regions to ensure a representative cell population.

Cell Culture and Growth Analysis

  • The isolated cells were cultured under laboratory conditions to assess their proliferation capacity.
  • Growth curves were generated to understand the optimal culture conditions, such as media composition and incubation parameters.
  • This analysis helped determine the best protocol for maintaining viable and proliferative equine lymph node endothelial cells.

Biomarker Characterization

  • An immunofluorescence assay was used to detect specific cellular markers, confirming the endothelial nature of the isolated cells.
  • Detected biomarkers included:
    • CD31: an endothelial cell adhesion molecule
    • ZO-1: a tight junction protein
    • CD79: commonly associated with B-cells, used here likely to rule out contamination
    • Beta-catenin and E-cadherin: involved in cell adhesion and signaling
    • LYE-1: a lymphatic endothelial marker
  • The presence of these markers validated that the primary cultured cells were of endothelial origin, specifically from lymph nodes.

Genomic Confirmation

  • Initial whole-genome sequencing was performed on the cultured cells.
  • The sequencing confirmed that the cells originated from the equine species, matching the NIH EquCab3.0 horse reference genome.
  • Comparison with the reference genome helped identify common genetic variations and ensured the integrity and identity of the cell culture.

Significance and Applications

  • This study is the first to report the successful establishment of primary endothelial cells derived from equine lymph nodes.
  • The model provides a valuable tool for equine biomedical research, replacing or supplementing in vivo studies.
  • Potential applications include:
    • Testing drug responses and pharmacodynamics relevant to equine health
    • Investigating molecular pathways involved in equine diseases
    • Studying environmental effects on lymphatic endothelial cells in horses
  • This advances veterinary cell biology and opens doors for more controlled mechanistic studies in equine medicine.

Cite This Article

APA
Lugo T, Myers S, Nguyen TA. (2025). Isolation and Characterization of Equine Lymph Node Endothelial Cells. Vet Sci, 12(9), 905. https://doi.org/10.3390/vetsci12090905

Publication

Veterinary sciences
ISSN: 2306-7381
NlmUniqueID: 101680127
Country: Switzerland
Language: English
Volume: 12
Issue: 9
PII: 905

Researcher Affiliations

Lugo, Tomas
  • School of Veterinary Medicine, Texas Tech University, Amarillo, TX 79106, USA.
Myers, Stephanie
  • School of Veterinary Medicine, Texas Tech University, Amarillo, TX 79106, USA.
Nguyen, Thu Annelise
  • School of Veterinary Medicine, Texas Tech University, Amarillo, TX 79106, USA.

Conflict of Interest Statement

The authors declare no conflicts of interest.

References

This article includes 52 references
  1. Willard-Mack CL. Normal Structure, Function, and Histology of Lymph Nodes. Toxicol. Pathol. 2006;34:409–424.
    doi: 10.1080/01926230600867727pubmed: 17067937google scholar: lookup
  2. Grant SM, Lou M, Yao L, Germain RN, Radtke AJ. The lymph node at a glance–how spatial organization optimizes the immune response. J. Cell Sci. 2020;133:jcs241828.
    doi: 10.1242/jcs.241828pmc: PMC7063836pubmed: 32144196google scholar: lookup
  3. Ozulumba T, Montalbine AN, Ortiz-Cárdenas JE, Pompano RR. New tools for immunologists: Models of lymph node function from cells to tissues. Front. Immunol. 2023;14:1183286.
    doi: 10.3389/fimmu.2023.1183286pmc: PMC10206051pubmed: 37234163google scholar: lookup
  4. Morgan EA. Surgical Pathology of Hematopoietic Neoplasms. Pathobiol. Hum. Dis. A Dyn. Encycl. Dis. Mech. 2014:3607–3627.
    doi: 10.1016/B978-0-12-386456-7.06908-2google scholar: lookup
  5. Pereira ER, Jones D, Jung K, Padera TP. The lymph node microenvironment and its role in the progression of metastatic cancer. Semin. Cell Dev. Biol. 2015;38:98–105.
    doi: 10.1016/j.semcdb.2015.01.008pmc: PMC4397158pubmed: 25620792google scholar: lookup
  6. Liao S, Padera TP. Lymphatic function and immune regulation in health and disease. Lymphat. Res. Biol. 2013;11:136–143.
    doi: 10.1089/lrb.2013.0012pmc: PMC3780287pubmed: 24024577google scholar: lookup
  7. Hammel JH, Cook SR, Belanger MC, Munson JM, Pompano RR. Modeling Immunity in Vitro: Slices, Chips, and Engineered Tissues. Annu. Rev. Biomed. Eng. 2021;23:461–491.
    doi: 10.1146/annurev-bioeng-082420-124920pmc: PMC8277680pubmed: 33872520google scholar: lookup
  8. Hughes JP, Rees SS, Kalindjian SB, Philpott KL. Principles of early drug discovery. Br. J. Pharmacol. 2011;162:1239–1249.
    doi: 10.1111/j.1476-5381.2010.01127.xpmc: PMC3058157pubmed: 21091654google scholar: lookup
  9. Ramaiahgari SC, den Braver MW, Herpers B, Terpstra V, Commandeur JNM, Van De Water B, Price LS. A 3D in vitro model of differentiated HepG2 cell spheroids with improved liver-like properties for repeated dose high-throughput toxicity studies. Arch. Toxicol. 2014;88:1083–1095.
    doi: 10.1007/s00204-014-1215-9pubmed: 24599296google scholar: lookup
  10. Roh TT, Chen Y, Rudolph S, Gee M, Kaplan DL. In Vitro Models of Intestine Innate Immunity. Trends Biotechnol. 2021;39:274–285.
    doi: 10.1016/j.tibtech.2020.07.009pmc: PMC7878199pubmed: 32854949google scholar: lookup
  11. Wang L, Hu D, Xu J, Hu J, Wang Y. Complex in vitro model: A transformative model in drug development and precision medicine. Clin. Transl. Sci. 2024;17:e13695.
    doi: 10.1111/cts.13695pmc: PMC10828975pubmed: 38062923google scholar: lookup
  12. Richter M, Piwocka O, Musielak M, Piotrowski I, Suchorska WM, Trzeciak T. From Donor to the Lab: A Fascinating Journey of Primary Cell Lines. Front. Cell Dev. Biol. 2021;9:711381.
    doi: 10.3389/fcell.2021.711381pmc: PMC8356673pubmed: 34395440google scholar: lookup
  13. Dietze K, Slosarek I, Fuhrmann-Selter T, Hopperdietzel C, Plendl J, Kaessmeyer S. Isolation of equine endothelial cells and life cell angiogenesis assay. Clin. Hemorheol. Microcirc. 2014;58:127–146.
    doi: 10.3233/CH-141877pubmed: 25227198google scholar: lookup
  14. Fidalgo-Carvalho I, Craigo JK, Barnes S, Costa-Ramos C, Montelaro RC. Characterization of an equine macrophage cell line: Application to studies of EIAV infection. Vet. Microbiol. 2009;136:8–19.
    doi: 10.1016/j.vetmic.2008.10.010pmc: PMC2689946pubmed: 19038510google scholar: lookup
  15. Lessiak U, Pratscher B, Tichy A, Nell B. Bevacizumab Efficiently Inhibits VEGF-Associated Cellular Processes in Equine Umbilical Vein Endothelial Cells: An In Vitro Characterization. Vet. Sci. 2023;10:632.
    doi: 10.3390/vetsci10110632pmc: PMC10675369pubmed: 37999456google scholar: lookup
  16. Bussche L., Van de Walle G.R.. Peripheral Blood-Derived Mesenchymal Stromal Cells Promote Angiogenesis via Paracrine Stimulation of Vascular Endothelial Growth Factor Secretion in the Equine Model. Stem Cells Transl. Med. 2014;3:1514–1525.
    doi: 10.5966/sctm.2014-0138pmc: PMC4250216pubmed: 25313202google scholar: lookup
  17. Bosseler L., Verryken K., Bauwens C., de Vries C., Deprez P., Ducatelle R., Vandenabeele S.. Equine multisystemic eosinophilic epitheliotropic disease: A case report and review of literature Equine multisystemic eosinophilic epitheliotropic disease: A case report and review of literature. N. Z. Vet. J. 2013;61:177–182.
    doi: 10.1080/00480169.2012.753569pubmed: 23441858google scholar: lookup
  18. Schumacher J., Edwards J.F., Cohen N.D.. Chronic Idiopathic Inflammatory Bowel Diseases of the Horse. J. Vet. Intern. Med. 2000;14:258–265.
    doi: 10.1111/j.1939-1676.2000.tb01164.xpubmed: 10830538google scholar: lookup
  19. Horan E.M., Metcalfe L.V.A., de Swarte M., Cahalan S.D., Katz L.M.. Pulmonary and hepatic eosinophilic granulomas and epistaxis in a horse suggestive of multi-systemic eosinophilic epitheliotropic disease. Equine Vet. Educ. 2013;25:607–613.
    doi: 10.1111/eve.12017google scholar: lookup
  20. Villagrán C.C., Vogt D., Gupta A., Fernández E.A.. Case Report Rapport de cas Inflammatory bowel disease characterized by multisystemic eosinophilic epitheliotropic disease (MEED) in a horse in Saskatchewan, Canada. Can. Vet. J. 2021;62:1190.
    pmc: PMC8543654pubmed: 34728845
  21. Paraschou G., Vogel P.E., Lee A.M., Trawford R.F., Priestnall S.L.. Multisystemic eosinophilic epitheliotropic disease in three donkeys. J. Comp. Pathol. 2023;201:105–108.
    doi: 10.1016/j.jcpa.2023.01.005pubmed: 36791600google scholar: lookup
  22. La Perle K.M.D., Piercy R.J., Long J.F., Blomme E.A.G.. Multisystemic, eosinophilic, epitheliotropic disease with intestinal lymphosarcoma in a horse. Vet. Pathol. 1998;35:144–146.
    doi: 10.1177/030098589803500209pubmed: 9539369google scholar: lookup
  23. Simon-Assmann P., Turck N., Sidhoum-Jenny M., Gradwohl G., Kedinger M.. In vitro models of intestinal epithelial cell differentiation. Cell Biol. Toxicol. 2007;23:241–256.
    pubmed: 17171431
  24. Wang Y., Gunasekara D.B., Attayek P.J., Reed M.I., DiSalvo M., Nguyen D.L., Dutton J.S., Lebhar M.S., Bultman S.J., Sims C.E.. In Vitro Generation of Mouse Colon Crypts. ACS Biomater. Sci. Eng. 2017;3:2502–2513.
    doi: 10.1021/acsbiomaterials.7b00368pmc: PMC6402816pubmed: 30854421google scholar: lookup
  25. Rooney M.F., Neto N.G.B., Monaghan M.G., Hill E.W., Porter R.K.. Conditionally immortalised equine skeletal muscle cell lines for in vitro analysis. Biochem. Biophys. Rep. 2023;33:101391.
    doi: 10.1016/j.bbrep.2022.101391pmc: PMC9727643pubmed: 36504704google scholar: lookup
  26. National Research Council . Monoclonal Antibody Production. National Academies Press; Washington, DC, USA: 1999. Summary of Advantages and Disadvantages of In Vitro and In Vivo Methods.
  27. Marycz K., Bourebaba N., Serwotka-Suszczak A., Mularczyk M., Galuppo L., Bourebaba L.. In Vitro Generated Equine Hepatic-Like Progenitor Cells as a Novel Potent Cell Pool for Equine Metabolic Syndrome (EMS) Treatment. Stem Cell Rev. Rep. 2023;19:1124–1134.
    doi: 10.1007/s12015-023-10507-3pmc: PMC10185601pubmed: 36658383google scholar: lookup
  28. Yuan Z.Q., Gault E., Gobeil P., Nixon C., Campo M., Nasir L.. Establishment and characterization of equine fibroblast cell lines transformed in vivo and in vitro by BPV-1: Model systems for equine sarcoids. Virology. 2008;373:352–361.
    doi: 10.1016/j.virol.2007.11.037pubmed: 18191170google scholar: lookup
  29. Evans E., Paillot R., López-Álvarez M.R.. A comprehensive analysis of e-CAS cell line reveals they are mouse macrophages. Sci. Rep. 2018;8:8237.
    doi: 10.1038/s41598-018-26512-3pmc: PMC5974405pubmed: 29844485google scholar: lookup
  30. Yu K., Chen B., Aran D., Charalel J., Yau C., Wolf D.M., van ‘t Veer L.J., Butte A.J., Goldstein T., Sirota M.. Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types. Nat. Commun. 2019;10:3574.
    doi: 10.1038/s41467-019-11415-2pmc: PMC6687785pubmed: 31395879google scholar: lookup
  31. Kaur G, Dufour J.M. Cell lines: Valuable tools or useless artifacts.. Spermatogenesis 2012;2:1–5.
    doi: 10.4161/spmg.19885pmc: PMC3341241pubmed: 22553484google scholar: lookup
  32. Lertkiatmongkol P, Liao D, Mei H, Hu Y, Newman P.J. Endothelial functions of PECAM-1 (CD31). Curr. Opin. Hematol. 2016;23:253–259.
    pmc: PMC4986701pubmed: 27055047
  33. Dave J.M, Bayless K.J. Vimentin as an integral regulator of cell adhesion and endothelial sprouting.. Microcirculation 2014;21:333–344.
    doi: 10.1111/micc.12111pubmed: 24387004google scholar: lookup
  34. Tornavaca O, Chia M, Dufton N, Almagro L.O, Conway D.E, Randi A.M, Schwartz M.A, Matter K, Balda M.S. ZO-1 controls endothelial adherens junctions, cell-cell tension, angiogenesis, and barrier formation.. J. Cell Biol. 2015;208:821–838.
    doi: 10.1083/jcb.201404140pmc: PMC4362456pubmed: 25753039google scholar: lookup
  35. Van Roy F, Berx G. The cell-cell adhesion molecule E-cadherin.. Cell. Mol. Life Sci. 2008;65:3756–3788.
    doi: 10.1007/s00018-008-8281-1pmc: PMC11131785pubmed: 18726070google scholar: lookup
  36. Johnson L.A, Prevo R, Clasper S, Jackson D.G. Inflammation-induced Uptake and Degradation of the Lymphatic Endothelial Hyaluronan Receptor LYVE-1.. J. Biol. Chem. 2007;282:33671–33680.
    doi: 10.1074/jbc.M702889200pubmed: 17884820google scholar: lookup
  37. Gordon E.J, Gale N.W, Harvey N.L. Expression of the hyaluronan receptor LYVE-1 is not restricted to the lymphatic vasculature; LYVE-1 is also expressed on embryonic blood vessels.. Dev. Dyn. 2008;237:1901–1909.
    doi: 10.1002/dvdy.21605pubmed: 18570254google scholar: lookup
  38. Banerji S, Ni J, Wang S.X, Clasper S, Su J, Tammi R, Jones M, Jackson D.G. LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan.. J. Cell Biol. 1999;144:789–801.
    doi: 10.1083/jcb.144.4.789pmc: PMC2132933pubmed: 10037799google scholar: lookup
  39. Jackson D.G. Hyaluronan in the lymphatics: The key role of the hyaluronan receptor LYVE-1 in leucocyte trafficking.. Matrix Biol. 2019;78–79:219–235.
    doi: 10.1016/j.matbio.2018.02.001pubmed: 29425695google scholar: lookup
  40. Jackson D.G. Biology of the lymphatic marker LYVE-1 and applications in research into lymphatic trafficking and lymphangiogenesis.. APMIS 2004;112:526–538.
    doi: 10.1111/j.1600-0463.2004.apm11207-0811.xpubmed: 15563314google scholar: lookup
  41. Wilting J, Papoutsi M, Christ B, Nicolaides K.H, Kaisenberg C.S, Borges J, Stark G.B, Alitalo K, Tomarev S.I, Niemeyer C. The transcription factor Prox1 is a marker for lymphatic endothelial cells in normal and diseased human tissues.. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 2002;16:1271–1273.
    pubmed: 12060670
  42. Sawa Y. New trends in the study of podoplanin as a cell morphological regulator.. Jpn. Dent. Sci. Rev. 2010;46:165–172.
    doi: 10.1016/j.jdsr.2010.01.003google scholar: lookup
  43. Quintanilla M, Montero L.M, Renart J, Villar E.M. Podoplanin in inflammation and cancer.. Int. J. Mol. Sci. 2019;20:707.
    doi: 10.3390/ijms20030707pmc: PMC6386838pubmed: 30736372google scholar: lookup
  44. Astarita J.L, Acton S.E, Turley S.J. Podoplanin: Emerging functions in development, the immune system, and cancer.. Front. Immunol. 2012;3:283.
    doi: 10.3389/fimmu.2012.00283pmc: PMC3439854pubmed: 22988448google scholar: lookup
  45. Vigl B, Aebischer D, Nitschké M, Iolyeva M, Röthlin T, Antsiferova O, Halin C. Tissue inflammation modulates gene expression of lymphatic endothelial cells and dendritic cell migration in a stimulus-dependent manner.. Blood 2011;118:205–215.
    doi: 10.1182/blood-2010-12-326447pubmed: 21596851google scholar: lookup
  46. Chu P.G, Arber D.A. CD79: A review.. Appl. Immunohistochem. Mol. Morphol. 2001;9:97–106.
    doi: 10.1097/00129039-200106000-00001pubmed: 11396639google scholar: lookup
  47. Cyster J.G, Allen C.D.C. B Cell Responses: Cell Interaction Dynamics and Decisions.. Cell 2019;177:524–540.
    doi: 10.1016/j.cell.2019.03.016pmc: PMC6538279pubmed: 31002794google scholar: lookup
  48. Ager A. High endothelial venules and other blood vessels: Critical regulators of lymphoid organ development and function.. Front. Immunol. 2017;8:45.
    doi: 10.3389/fimmu.2017.00045pmc: PMC5289948pubmed: 28217126google scholar: lookup
  49. Hussain B, Kasinath V, Ashton-Rickardt G.P, Clancy T, Uchimura K, Tsokos G, Abdi R. High endothelial venules as potential gateways for therapeutics.. Trends Immunol. 2022;43:728–740.
    doi: 10.1016/j.it.2022.07.002pmc: PMC10804419pubmed: 35931612google scholar: lookup
  50. Vella G, Guelfi S, Bergers G. High Endothelial Venules: A Vascular Perspective on Tertiary Lymphoid Structures in Cancer.. Front. Immunol. 2021;12:736670.
    doi: 10.3389/fimmu.2021.736670pmc: PMC8416033pubmed: 34484246google scholar: lookup
  51. Blanchard L, Girard J.P. High endothelial venules (HEVs) in immunity, inflammation and cancer.. Angiogenesis 2021;24:719–753.
    doi: 10.1007/s10456-021-09792-8pmc: PMC8487881pubmed: 33956259google scholar: lookup
  52. Zhu W, Zheng D, Wang D, Yang L, Zhao C, Huang X. Emerging Roles of Ubiquitin-Specific Protease 25 in Diseases.. Front. Cell Dev. Biol. 2021;9:698751.
    doi: 10.3389/fcell.2021.698751pmc: PMC8262611pubmed: 34249948google scholar: lookup

Citations

This article has been cited 0 times.
Subscribe to our newsletter
Join 99,002 horse owners like you who receive our email updates on horse health and nutrition.